功能性肠病中肠道微生物群的治疗性调节
Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders.
作者信息
Lee Hyo Jeong, Choi Jong Kyoung, Ryu Han Seung, Choi Chang Hwan, Kang Eun Hee, Park Kyung Sik, Min Yang Won, Hong Kyoung Sup
机构信息
Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Department of Internal Medicine, National Medical Center, Seoul, Korea.
出版信息
J Neurogastroenterol Motil. 2017 Jan 30;23(1):9-19. doi: 10.5056/jnm16124.
Abstract
Functional bowel disorders (FBDs) are functional gastrointestinal disorders with symptoms attributable to the middle or lower gastrointestinal tract. These include irritable bowel syndrome, functional bloating, functional constipation, functional diarrhea, and unspecified FBD. Increasing evidence has emerged of late that intestinal microbiota is involved in the pathogenesis of FBDs. In this review, the therapeutic benefits and future perspectives of the currently available strategies for modifying the gut microbiota in FBDs are described, focusing primarily on irritable bowel syndrome and functional constipation.
摘要
功能性肠病（FBDs）是一类功能性胃肠疾病，其症状归因于中、下消化道。这些疾病包括肠易激综合征、功能性腹胀、功能性便秘、功能性腹泻以及未特定的功能性肠病。近来，越来越多的证据表明肠道微生物群参与了功能性肠病的发病机制。在本综述中，描述了目前用于改变功能性肠病肠道微生物群的策略的治疗益处和未来前景，主要聚焦于肠易激综合征和功能性便秘。
相似文献
1
Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders.
J Neurogastroenterol Motil. 2017 Jan 30;23(1):9-19. doi: 10.5056/jnm16124.
2
Washed microbiota transplantation improves symptoms and intestinal barrier function in patients with functional bowel disorders: a propensity-score matching analysis.
BMC Gastroenterol. 2024 Jan 23;24(1):45. doi: 10.1186/s12876-024-03131-z.
3
Probiotics in functional bowel disorders.
Best Pract Res Clin Gastroenterol. 2016 Feb;30(1):89-97. doi: 10.1016/j.bpg.2016.01.003. Epub 2016 Jan 14.
4
Dysbiosis in Functional Bowel Disorders.
Ann Nutr Metab. 2018;72(4):296-306. doi: 10.1159/000488773. Epub 2018 Apr 25.
5
The Gut Microbiome in Irritable Bowel Syndrome and Other Functional Bowel Disorders.
Gastroenterol Clin North Am. 2017 Mar;46(1):91-101. doi: 10.1016/j.gtc.2016.09.014.
6
Five-year follow-up of 263 cases of functional bowel disorder.
World J Gastroenterol. 2013 Mar 7;19(9):1466-71. doi: 10.3748/wjg.v19.i9.1466.
7
Gut Microbiota and Chronic Constipation: A Review and Update.
Front Med (Lausanne). 2019 Feb 12;6:19. doi: 10.3389/fmed.2019.00019. eCollection 2019.
8
The effect of fecal microbiota transplantation on psychiatric symptoms among patients with irritable bowel syndrome, functional diarrhea and functional constipation: An open-label observational study.
J Affect Disord. 2018 Aug 1;235:506-512. doi: 10.1016/j.jad.2018.04.038. Epub 2018 Apr 12.
9
Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom.
Gastroenterology. 2020 Apr;158(5):1262-1273.e3. doi: 10.1053/j.gastro.2019.12.021. Epub 2020 Jan 7.
10
[Therapeutic modulation of intestinal microbiota in irritable bowel syndrome. From probiotics to fecal microbiota therapy].
MMW Fortschr Med. 2017 Dec;159(Suppl 7):1-5. doi: 10.1007/s15006-017-0338-3. Epub 2017 Dec 4.
引用本文的文献
1
Probiotics interventions modulating gut microbiota composition in individuals with intestinal constipation: Protocol of a systemic review and meta-analysis of randomized controlled trials.
PLoS One. 2025 Jan 24;20(1):e0311799. doi: 10.1371/journal.pone.0311799. eCollection 2025.
2
Functional Abdominal Bloating and Gut Microbiota: An Update.
Microorganisms. 2024 Aug 14;12(8):1669. doi: 10.3390/microorganisms12081669.
3
The Effect of on Gut Microbial Changes and Functional Profiles of Metabolism in High-fat Diet-fed Rats Depending on Age and Sex.
J Neurogastroenterol Motil. 2024 Apr 30;30(2):236-250. doi: 10.5056/jnm23096.
4
Effect of Probiotic Therapy on Hemodynamic Response Associated with Systemic Inflammatory Reaction and Antibiotic-Induced Dysbiosis in Chronic Experiments in Rats.
Bull Exp Biol Med. 2022 Apr;172(6):676-680. doi: 10.1007/s10517-022-05455-w. Epub 2022 May 2.
5
Validity and safety of ID-JPL934 in lower gastrointestinal symptom improvement.
Sci Rep. 2021 Jun 22;11(1):13046. doi: 10.1038/s41598-021-92007-3.
6
Development of a freeze-dried symbiotic obtained from rice bran.
Biotechnol Rep (Amst). 2021 May 24;30:e00636. doi: 10.1016/j.btre.2021.e00636. eCollection 2021 Jun.
7
Effect of Combined Live Probiotics Alleviating the Gastrointestinal Symptoms of Functional Bowel Disorders.
Gastroenterol Res Pract. 2020 Sep 17;2020:4181748. doi: 10.1155/2020/4181748. eCollection 2020.
8
Potential common factors associated with predisposition to common cold in middle-aged and elderly Japanese: A community-based cross-sectional study.
Medicine (Baltimore). 2018 May;97(20):e10729. doi: 10.1097/MD.0000000000010729.
9
Systematic review: probiotics in the management of lower gastrointestinal symptoms - an updated evidence-based international consensus.
Aliment Pharmacol Ther. 2018 Apr;47(8):1054-1070. doi: 10.1111/apt.14539. Epub 2018 Feb 20.
10
Gut Microbiota and Salivary Diagnostics: The Mouth Is Salivating to Tell Us Something.
Biores Open Access. 2017 Oct 1;6(1):123-132. doi: 10.1089/biores.2017.0020. eCollection 2017.
本文引用的文献
1
Breath Testing for Small Intestinal Bacterial Overgrowth: A Means to Enrich Rifaximin Responders in IBS Patients?
Am J Gastroenterol. 2016 Mar;111(3):305-6. doi: 10.1038/ajg.2016.32. Epub 2016 Mar 1.
2
A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial.
Eur J Gastroenterol Hepatol. 2016 Mar;28(3):281-9. doi: 10.1097/MEG.0000000000000557.
3
Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
Aliment Pharmacol Ther. 2016 Jan;43 Suppl 1:37-49. doi: 10.1111/apt.13437.
4
Review article: the antimicrobial effects of rifaximin on the gut microbiota.
Aliment Pharmacol Ther. 2016 Jan;43 Suppl 1:3-10. doi: 10.1111/apt.13434.
5
Predicting a Response to Antibiotics in Patients with the Irritable Bowel Syndrome.
Dig Dis Sci. 2016 Mar;61(3):846-51. doi: 10.1007/s10620-015-3872-9. Epub 2015 Sep 11.
6
The gut microbiota and host health: a new clinical frontier.
Gut. 2016 Feb;65(2):330-9. doi: 10.1136/gutjnl-2015-309990. Epub 2015 Sep 2.
7
Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial.
Gastroenterology. 2015 Nov;149(6):1399-1407.e2. doi: 10.1053/j.gastro.2015.07.054. Epub 2015 Aug 5.
8
Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome.
Sci Rep. 2015 Aug 4;5:12693. doi: 10.1038/srep12693.
9
Non-Celiac Gluten Sensitivity Has Narrowed the Spectrum of Irritable Bowel Syndrome: A Double-Blind Randomized Placebo-Controlled Trial.
Nutrients. 2015 Jun 5;7(6):4542-54. doi: 10.3390/nu7064542.
10
Fecal Microbiota Transplantation for Ulcerative Colitis: Not Just Yet.
Gastroenterology. 2015 Jul;149(1):15-8. doi: 10.1053/j.gastro.2015.05.030. Epub 2015 May 27.
Zotero 插件